Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Antigen-specific IgT cells
- Development stage
- Unknown
- Lead developer
- Shenzhen Geno-Immune Medical Institute
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
Antigen-specific IgT cells are an investigational autologous cell therapy developed by the Shenzhen Geno-Immune Medical Institute for the treatment of recurrent glioblastoma multiforme (GBM). The therapy consists of a patient's own T cells that have been genetically modified to recognize specific GBM tumor antigens and to express immune modulatory genes, such as those encoding immune checkpoint inhibitors. This dual-modality approach is designed to directly target and eliminate tumor cells while simultaneously modulating the immunosuppressive tumor microenvironment to enhance the anti-tumor immune response. The therapy is currently being evaluated in Phase 1 clinical trials (e.g., NCT03170141) for patients with recurrent GBM, diffuse intrinsic pontine glioma (DIPG), and diffuse midline glioma (DMG), often following lymphodepleting chemotherapy.
- Other names
- Immunogene-modified Antigen-specific T cellsIgT
02
Targets
Checkpoint (Immune checkpoints)
Beyond the preview
Go deeper on Antigen-specific IgT cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Antigen-specific IgT cells.